UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 29th July
2020, London, UK and Paris, France
GlaxoSmithKline plc ("GSK")
Sanofi and GSK agree with the UK government to supply up to 60
million doses of COVID-19 vaccine
●
Agreement
relates to vaccine candidate using Sanofi's recombinant
protein-based technology combined with GSK's pandemic adjuvant
system
●
Both
companies are committed to making their COVID-19 vaccine candidate
affordable and available globally
Sanofi and have reached an agreement, subject to final
contract, with the UK government for the supply of up to 60 million
doses of a COVID-19 vaccine. The vaccine candidate, developed by
Sanofi in partnership with GSK, is based on the recombinant
protein-based technology used by Sanofi to produce an influenza
vaccine, and GSK's established pandemic adjuvant
technology.
"With our partner GSK, we are pleased to cooperate with the UK
government as well as several other countries and global
organizations as part of our ongoing efforts to develop a safe and
effective vaccine and make it available as quickly as possible. We
greatly appreciate the UK government's support of this shared
vision," said Thomas Triomphe, Executive Vice President and Global
Head of Sanofi Pasteur.
Roger Connor, President of GSK Vaccines added, "We believe that
this adjuvanted vaccine candidate has the potential to play a
significant role in overcoming the COVID-19 pandemic, both in the
UK and around the world. We thank the UK Government for
confirmation of purchasing intent, which supports the significant
investment we are already making as a company to scale up
development and production of this vaccine."
Sanofi is leading the clinical development and registration of the
COVID-19 vaccine and expects a Phase 1/2 study to start in
September, followed by a Phase 3 study by the end of 2020. If
the data are positive, regulatory approval could be achieved by the
first half of 2021. In parallel, Sanofi and GSK are scaling
up manufacturing of the antigen and adjuvant to produce up to one
billion doses per year overall.
UK Business Secretary Alok Sharma said: "Our scientists
and researchers are racing to find a safe and effective vaccine at
a speed and scale never seen before. While this progress is truly
remarkable, the fact remains that there are no
guarantees.
"In the meantime, it is important that we secure early access to a
diverse range of promising vaccine candidates, like GSK and Sanofi,
to increase our chances of finding one that works so we can protect
the public and save lives."
Kate Bingham, Chair of the UK Government's Vaccines Taskforce,
said: "Through this agreement with GSK and Sanofi, the Vaccine
Taskforce can add another type of vaccine to the three different
types of vaccine we have already secured.
"This diversity of vaccine types is important because we do not yet
know which, if any, of the different types of vaccine will prove to
generate a safe and protective response to COVID-19. Whilst
this agreement is very good news, we mustn't be complacent or over
optimistic.
"The fact remains we may never get a vaccine and if we do get one,
we have to be prepared that it may not be a vaccine which prevents
getting the virus, but rather one that reduces
symptoms."
Sanofi and GSK are committed to making the vaccine available
globally
Active discussions on supply of the vaccine are ongoing with global
organizations, the US and the EU Commission - with France and Italy
on the negotiation team. The partners plan to provide a
significant portion of total worldwide available supply capacity in
2021/22, to the global initiative"Access to COVID‐19
Tools (ACT) Accelerator", a global collaboration of leaders of
governments, global health organizations, businesses and
philanthropies to accelerate development, production, and equitable
access to COVID-19 tests, treatments, and
vaccines.
GSK commitment to tackling COVID-19
GSK is collaborating with companies and research groups across the
world working on promising COVID-19 vaccine candidates through the
use of our innovative vaccine adjuvant technology. The use of an
adjuvant is of particular importance in a pandemic situation since
it may reduce the amount of vaccine protein required per dose,
allowing more vaccine doses to be produced and therefore
contributing to protecting more people. GSK does not expect
to profit from COVID-19 vaccines during the pandemic phase, and
will invest any short-term profit in coronavirus related research
and long-term pandemic preparedness, either through GSK internal
investments or with external partners.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
GSK enquiries:
|
|
|
|
Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
Analyst/Investor enquiries:
|
Sarah Elton-Farr
|
+44 (0) 20 8047 5194
|
(London)
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
Danielle Smith
|
+44 (0) 20 8047 0932
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
29, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024